Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Genes, Chromosomes & Cancer|November 20, 2013
Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic indexClémentine Sarkozy, Christine Terré, Fabrice Jardin, et al.
The Lancet. Haematology|January 3, 2017
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA groupFrédéric Peyrade, Serge Bologna, Vincent Delwail, et al.
The Pan African Medical Journal|June 3, 2024
Efficacy of daprodustat for patients on dialysis with anemia: systematic review and network meta-analysisHammad Ali Fadlalmola, Khaled Mohammed Al-Sayaghi, Abdulqader Abdlah Al-Hebshi, et al.
Journal of Patient Safety|March 20, 2024
Enhancing Patient Safety in Prehospital Environment: Analyzing Patient Perspectives on Non-Transport Decisions With Natural Language Processing and Machine LearningHassan Farhat, Guillaume Alinier, Reem Tluli, et al.
Leukemia & Lymphoma|November 29, 2017
Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemiaMathilde Ruggiu, Florence Oberkampf, David Ghez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2021
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or OlderLucie Oberic, Frederic Peyrade, Mathieu Puyade, et al.
Health Security|February 9, 2024
Perspectives on Preparedness for Chemical, Biological, Radiological, and Nuclear Threats in the Middle East and North Africa Region: Application of Artificial Intelligence TechniquesHassan Farhat, Guillaume Alinier, Mariana Helou, et al.
The Lancet. Oncology|January 20, 2019
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 studyRené-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP TrialVincent Camus, Catherine Thieblemont, Philippe Gaulard, et al.
Blood Advances|August 4, 2025
Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II StudyOlivier Tournilhac, Krimo Bouabdallah, Solene Lecolant, et al.
Pageof 4